CN115317675B - Drug eluting stent and preparation method and application thereof - Google Patents
Drug eluting stent and preparation method and application thereof Download PDFInfo
- Publication number
- CN115317675B CN115317675B CN202211011374.4A CN202211011374A CN115317675B CN 115317675 B CN115317675 B CN 115317675B CN 202211011374 A CN202211011374 A CN 202211011374A CN 115317675 B CN115317675 B CN 115317675B
- Authority
- CN
- China
- Prior art keywords
- drug eluting
- stent
- eluting stent
- drug
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 123
- 229940079593 drug Drugs 0.000 title claims abstract description 107
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000011159 matrix material Substances 0.000 claims abstract description 38
- 239000000017 hydrogel Substances 0.000 claims abstract description 30
- 238000007789 sealing Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229920001661 Chitosan Polymers 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 11
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 11
- 229960002930 sirolimus Drugs 0.000 claims description 11
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- MIMUSZHMZBJBPO-UHFFFAOYSA-N 6-methoxy-8-nitroquinoline Chemical compound N1=CC=CC2=CC(OC)=CC([N+]([O-])=O)=C21 MIMUSZHMZBJBPO-UHFFFAOYSA-N 0.000 claims description 8
- 230000007797 corrosion Effects 0.000 claims description 8
- 238000005260 corrosion Methods 0.000 claims description 8
- 238000005470 impregnation Methods 0.000 claims description 8
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 6
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 6
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 claims description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 5
- 229910017604 nitric acid Inorganic materials 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 235000007240 daidzein Nutrition 0.000 claims description 3
- 238000005530 etching Methods 0.000 claims description 3
- 229960005167 everolimus Drugs 0.000 claims description 3
- 229940038384 octadecane Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000010333 potassium nitrate Nutrition 0.000 claims description 3
- 239000004323 potassium nitrate Substances 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 2
- 102400001047 Endostatin Human genes 0.000 claims description 2
- 108010079505 Endostatins Proteins 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000006 Nitroglycerin Substances 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000007994 TES buffer Substances 0.000 claims description 2
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims description 2
- 229960003856 argatroban Drugs 0.000 claims description 2
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 claims description 2
- MQKXWEJVDDRQKK-UHFFFAOYSA-N bis(6-methylheptyl) butanedioate Chemical compound CC(C)CCCCCOC(=O)CCC(=O)OCCCCCC(C)C MQKXWEJVDDRQKK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003518 caustics Substances 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- 229960002086 dextran Drugs 0.000 claims description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002768 dipyridamole Drugs 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims description 2
- 235000002780 gingerol Nutrition 0.000 claims description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960001008 heparin sodium Drugs 0.000 claims description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229960002460 nitroprusside Drugs 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 229940076279 serotonin Drugs 0.000 claims description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 claims description 2
- 235000010344 sodium nitrate Nutrition 0.000 claims description 2
- 239000004317 sodium nitrate Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 2
- 229960005314 suramin Drugs 0.000 claims description 2
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims description 2
- 229950009819 zotarolimus Drugs 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims 1
- 229960001123 epoprostenol Drugs 0.000 claims 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims 1
- 239000011248 coating agent Substances 0.000 abstract description 16
- 238000000576 coating method Methods 0.000 abstract description 16
- 208000037803 restenosis Diseases 0.000 abstract description 11
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 238000004090 dissolution Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 11
- 229940045110 chitosan Drugs 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229960003160 hyaluronic acid Drugs 0.000 description 6
- 238000004506 ultrasonic cleaning Methods 0.000 description 6
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229960001631 carbomer Drugs 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910001000 nickel titanium Inorganic materials 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005077 saccule Anatomy 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 238000004528 spin coating Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- -1 carbomer 940 Chemical compound 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 229940085237 carbomer-980 Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000006056 electrooxidation reaction Methods 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The invention provides a drug eluting stent, a preparation method and application thereof. The drug eluting stent comprises a stent matrix, a drug and hydrogel; the surface of the bracket matrix is provided with micro holes, and the medicine is loaded in the micro holes and sealed by hydrogel. The drug eluting stent has no risk of coating falling off, and reduces the occurrence probability of restenosis, wherein the drug is loaded in micropores on the surface of the stent and is not easy to be scoured by blood flow; and hydrogel hole sealing is adopted to avoid sudden release caused by too fast dissolution of the medicine.
Description
Technical Field
The invention belongs to the technical field of implantable medical devices, and particularly relates to a drug eluting stent, a preparation method and application thereof.
Background
Atherosclerosis is one of the serious diseases threatening human health, and stent placement is one of the main means for treating atherosclerosis. Early simple bare saccule expansion and bare stent implantation easily lead to high restenosis rate and poor treatment effect. At present, the Drug Eluting Stent (DES) is widely applied to clinic, and can reduce the restenosis rate to below 10 percent. Although the drug eluting stent can greatly reduce restenosis rate, the effect of complete radical cure is not achieved. It is probably due to the fact that, as soon as the drug is usually supported on a polymer carrier, the polymer carrier itself may have side effects on the human body, inducing restenosis of the stent. Secondly, the combination of the coating and the stent is not firm, the stent is easy to fall off in the process of pressing and holding and expanding the stent, or the effective action of the drug is reduced due to uneven degradation and falling in the body, and the treatment effect is affected. Thus, the design concept of the new drug eluting stent is to eliminate the polymer coating.
CN112386377a discloses a drug-loaded punctiform stent and a preparation method thereof, which are mainly used for the interlayer after the below-knee artery saccule dilatation molding operation. The stent comprises a shorter nickel-titanium alloy stent matrix, the stent matrix is of a self-expanding grid design structure, the surface of the stent matrix is provided with uniform drug-carrying micro-pits, and a drug coating is coated on the surface of the uniform drug-carrying micro-pits: the preparation method comprises 1) processing nickel-titanium alloy into bracket matrix; 2) Treating the surface of a bracket matrix; 3) Carrying out corrosion treatment on the bracket matrix; 4) Cleaning the corroded bracket matrix; 5) And (3) coating the surface of the stent matrix with the micro pits with the medicine. The drug-loaded punctiform stent is formed by combining a shorter longitudinal length with an open pore design, so that the metal load on arterial blood vessels is reduced to the greatest extent, the surface area contacted with the arterial blood vessels is reduced, the stent is not easy to break and is suitable for various blood vessel diameters, the coated drugs on the surface of the stent can be released controllably, the stent matrix fully plays the supporting and drug treatment effects, and the occurrence rate of restenosis and target lesion blood transport reconstruction is reduced. However, the electrochemical corrosion adopted by the method needs to connect the anode and the bracket, and the connection part of the anode and the bracket can be shielded, so that the bracket is corroded unevenly.
CN1919353a discloses a method for manufacturing a micro blind hole medicine carrying layer on the surface of a metal bracket, which comprises the following steps: a. treating the surface of the metal bracket by using a heated NaOH solution, removing the existing impurities and oxide films, then washing by using deionized water, and drying; b. accurately preparing corrosive liquid by using analytically pure acid at normal temperature, and calibrating the corrosive liquid; c. immersing the treated metal bracket into the calibrated corrosive liquid at normal temperature, taking out, washing with deionized water, and drying; d. preparing an organic solution with a certain concentration by using a volatile organic solvent and a medicament carried by a metal bracket at normal temperature; e. at normal temperature, the metal bracket with micro blind holes formed on the surface is put into an organic solution containing the carried medicine, and is taken out and dried after microwave oscillation. The nickel titanium and stainless steel are stable, so that the reaction rate is slow at normal temperature. Therefore, the method requires a corrosion time of up to 16 hours, and the preparation efficiency is low.
CN101869723a discloses a composite drug stent for inhibiting cardiovascular restenosis and a preparation method thereof, the stent is made of metal pipe by laser cutting, the surface of the stent is corroded by electrochemical acid solution to form nano holes, a layer of non-degradable bioactive coating is sprayed on the surface of the main body, the thickness is 10-50 microns, and a layer of degradable biocompatible polymer drug coating is sprayed outside the non-degradable bioactive coating, and the thickness is 10-100 microns. Wherein the non-degradable bioactive coating is prepared by mixing a non-degradable biocompatible high polymer, an active biological component, an organic solvent and the like to form a solution, and spraying, drying and other procedures. The method also adopts an electrochemical method, and the phenomenon of uneven corrosion caused by shielding the clamp and the bracket is also existed.
The above patents have more or less such drawbacks. In fact, the ideal effect achieved by the drug coating should be that the drug is uniformly distributed on the stent surface, attached to the matrix after implantation, and released slowly during long-term (> 1 year) service to achieve sustained therapeutic effect.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a drug eluting stent, and a preparation method and application thereof. The invention prepares nano-scale and submicron-scale corrosion holes on the surface of a bracket matrix by a chemical corrosion method, fully impregnates and loads the drugs in the holes, and then seals the holes through hydrogel.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the present invention provides a drug eluting stent comprising a stent matrix, a drug and a hydrogel; wherein, the surface of the bracket matrix is provided with micro holes, and the medicine is loaded in the micro holes and sealed by hydrogel.
In the invention, the drug is loaded in the micropores on the surface of the stent matrix, the micropores are sealed by the hydrogel, the drug eluting stent has no risk of coating falling off, and the occurrence probability of restenosis is reduced, wherein the drug is loaded in the micropores on the surface of the stent, and is not easy to be flushed by blood flow; and hydrogel hole sealing is adopted to avoid sudden release caused by too fast dissolution of the medicine.
Preferably, the micropores are spherical, and the diameter of the micropores is 0.2-0.9 μm, for example, 0.2 μm, 0.3 μm, 0.4 μm, 0.5 μm, 0.6 μm, 0.7 μm, 0.8 μm, 0.9 μm, etc.
Preferably, the distribution density of the micro holes on the surface of the bracket matrix is 4-8 ten thousand/mm 2 For example, 4 ten thousand pieces/mm 2 4.5 ten thousand/mm 2 5 ten thousand pieces/mm 2 5.5 ten thousand/mm 2 6 ten thousand/mm 2 6.5 ten thousand/mm 2 7 ten thousand/mm 2 7.5 ten thousand/mm 2 8 ten thousand pieces/mm 2 Etc.
Preferably, the drug is selected from any one or a combination of at least two of rapamycin, everolimus, zotarolimus, paclitaxel, gingerol, losartan, daidzein, docetaxel, dexamethasone, methotrexate, dextran, mitomycin, heparin sodium, doxorubicin hydrochloride, hirudin, argatroban, dipyridamole, prostacyclin analogues, nitroglycerin, nitroprusside, suramin, endostatin, serotonin blockers, steroids or oligopeptides.
Preferably, the hydrogel is selected from any one or a combination of at least two of agar, polyvinyl alcohol, polyvinylpyrrolidone, alginic acid, hyaluronic acid, gelatin, chitosan, cellulose, fibrin or carbomer.
Preferably, the polyvinyl alcohol has a number average molecular weight of 47000 to 98000, and may be 47000, 50000, 55000, 60000, 65000, 70000, 75000, 80000, 85000, 90000, 95000, 98000, or the like, for example.
Preferably, the number average molecular weight of the polyvinylpyrrolidone is 8000-1300000, and may be 8000, 10000, 50000, 100000, 200000, 400000, 600000, 800000, 1000000, 1200000, 1300000, or the like, for example.
Preferably, the molecular weight of the hyaluronic acid is 400000-2500000, and for example, 400000, 600000, 800000, 1000000, 1200000, 1400000, 1600000, 1800000, 2000000, 2200000, 2500000 and the like can be used.
Preferably, the carbomer is selected from any one or a combination of at least two of carbomer 934, carbomer 940, carbomer 941 or carbomer 980.
Preferably, the hydrogel is any one or a combination of at least two of chitosan, polyvinyl alcohol and polyvinylpyrrolidone, and the mass ratio of the chitosan to the polyvinyl alcohol to the polyvinylpyrrolidone is 1 (2-4), for example, 1:2:2, 1:2:3, 1:2:4, 1:3:2, 1:3:3, 1:3:4, and the like.
Preferably, the hydrogel is a combination of chitosan, sodium alginate and polyvinylpyrrolidone, and the mass ratio of the chitosan, sodium alginate and polyvinylpyrrolidone is 1 (0.5-2): (4-6), for example, may be 1:0.5:4, 1:0.5:5, 1:0.5:6, 1:1:4, 1:1:5, 1:1:6, 1:2:4, 1:2:5, 1:2:6, etc.
Preferably, the hydrogel is a combination of gelatin and hyaluronic acid, the mass ratio of gelatin to hyaluronic acid being (5-20): 1, for example, 5:1, 6:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 16:1, 18:1, 20:1, etc.
Preferably, the drug-eluting stent has a drug-loading density of 1-5 mug/mm 2 For example, it may be 1. Mu.g/mm 2 、1.5μg/mm 2 、2μg/mm 2 、2.5μg/mm 2 、3μg/mm 2 、3.5μg/mm 2 、4μg/mm 2 、4.5μg/mm 2 、5μg/mm 2 Etc.
In a second aspect, the present invention provides a method for preparing a drug eluting stent as described in the first aspect, the method comprising the steps of:
(1) Carrying out chemical corrosion treatment on the surface of the bracket matrix, and forming micro holes on the surface of the bracket matrix;
(2) Immersing the stent matrix treated in the step (1) in a drug solution to load the drug into the micropores;
(3) And (3) sealing the stent matrix treated in the step (2) by using hydrogel to obtain the drug eluting stent.
The invention provides a medicine elution branch without coating and a preparation method thereof, in particular to a preparation method of medicine loaded on the surface of a bracket. Wherein, the chemical corrosion method is to accelerate the reaction of the bracket in the reaction kettle under the action of high temperature and high pressure.
Preferably, in step (1), the step of the chemical etching treatment is: placing the bracket matrix and the corrosive liquid into a reaction kettle, and reacting under the conditions of high temperature and high pressure.
Preferably, the etching solution includes an etchant, a surfactant, and a solvent.
Preferably, the corrosive liquid consists of the following components in percentage by mass based on 100% of the total mass of the corrosive liquid: 0.5 to 10 percent (for example, 0.5 percent, 1 percent, 2 percent, 3 percent, 4 percent, 5 percent, 6 percent, 7 percent, 8 percent, 9 percent, 10 percent and the like) of corrosive agent, 0.1 to 5 percent (for example, 0.5 percent, 1 percent, 2 percent, 3 percent, 4 percent, 5 percent and the like) of surfactant, and the balance of solvent.
Preferably, the etchant is selected from any one or a combination of at least two of hydrofluoric acid, ammonium fluoride, ammonium bifluoride, nitric acid, sodium nitrate, ammonium nitrate, potassium nitrate or ammonium bifluoride.
Preferably, the surfactant is selected from any one or a combination of at least two of diisooctyl succinate, sodium dodecyl benzene sulfonate, cetyltrimethylammonium bromide or triethanolamine.
Preferably, the solvent is selected from any one or a combination of at least two of PBS solvent, TES buffer, acetone, diethyl ether, isopropanol, n-pentane, cyclopentane, decane, octadecane or polyethylene glycol.
Preferably, the temperature of the reaction is 110-250deg.C, for example 110 deg.C, 120 deg.C, 140 deg.C, 160 deg.C, 180 deg.C, 200 deg.C, 220 deg.C, 250 deg.C, etc., and the reaction time is 60-360min, for example 60min, 80min, 100min, 150min, 200min, 250min, 300min, 360min, etc.
Preferably, in step (2), the solvent of the drug solution is selected from any one or a combination of at least two of methanol, ethanol or dichloromethane.
Preferably, in the step (2), the concentration of the drug solution is 10-50mg/mL, for example, 10mg/mL, 15mg/mL, 20mg/mL, 25mg/mL, 30mg/mL, 35mg/mL, 40mg/mL, 45mg/mL, 50mg/mL, etc.
Preferably, in the step (2), the temperature of the impregnation is 0 to 20 ℃, for example, 0 ℃,2 ℃,5 ℃, 8 ℃, 10 ℃, 12 ℃, 15 ℃, 20 ℃ and the like, and the time of the impregnation is 30 to 120min, for example, 30min, 40min, 50min, 60min, 80min, 100min, 120min and the like.
Preferably, in the step (3), the step of sealing the hole is: and (3) ultrasonically spraying the mixed solution of the hydrogel onto the surface of a stent matrix, and then solidifying and drying to finish hole sealing to obtain the drug eluting stent.
Or, the hole sealing step is as follows: soaking a stent matrix in a mixed solution of hydrogel, lifting, centrifuging, solidifying and drying to finish hole sealing, and obtaining the drug eluting stent.
Preferably, in step (3), the solvent of the mixed solution of hydrogels is water.
Preferably, in the step (3), the solid content of the mixed solution of the hydrogel is 10 to 50wt%, for example, 10wt%, 15wt%, 20wt%, 25wt%, 30wt%, 35wt%, 40wt%, 45wt%, 50wt%, etc.
Preferably, in the step (3), the power of the ultrasonic spraying is 3-15W, for example, 3W, 4W, 5W, 6W, 7W, 8W, 9W, 10W, 11W, 12W, 13W, 14W, 15W, etc., the frequency is 50-150kHz, for example, 50kHz, 60kHz, 80kHz, 100kHz, 120kHz, 150kHz, etc., and the speed is 0.01-2mL/min, for example, 0.01mL/min, 0.05mL/min, 0.1mL/min, 0.2mL/min, 0.4mL/min, 0.5mL/min, 1mL/min, 1.2mL/min, 1.4mL/min, 1.6mL/min, 1.8mL/min, 2mL/min, etc.
Preferably, in the step (3), the temperature of the impregnation is 20-40 ℃, for example, 20 ℃, 25 ℃,30 ℃, 35 ℃, 40 ℃ and the like, and the time of the impregnation is 0.5-10min, for example, 0.5min, 1min, 2min, 3min, 4min, 5min, 6min, 7min, 8min, 9min, 10min and the like.
Preferably, in the step (3), the rotation speed of the centrifugal treatment is 100-1000r/min, for example, 100r/min, 200r/min, 300r/min, 400r/min, 500r/min, 600r/min, 800r/min, 1000r/min, etc.
Preferably, in the step (3), the curing is ultraviolet curing, and the wavelength of ultraviolet curing is 300-380nm, for example, 300nm, 310nm, 320nm, 330nm, 340nm, 350nm, 360nm, 370nm, 380nm, etc., and the time of ultraviolet curing is 20-40min, for example, 20min, 25min, 30min, 35min, 40min, etc.
In a third aspect, the present invention provides the use of a drug eluting stent as described in the first aspect for the preparation of a product for the treatment of atherosclerosis.
Compared with the prior art, the invention has the following beneficial effects:
(1) The drug eluting stent disclosed by the invention does not contain a drug carrier coating, does not have the risk of coating falling off, and reduces the occurrence probability of restenosis;
(2) The medicine in the medicine elution bracket is loaded in the micropores on the surface of the bracket, so that the medicine is not easy to be washed by blood flow;
(3) The drug eluting stent adopts hydrogel hole sealing, so that burst release caused by too fast dissolution of the drug can be well avoided;
(4) The preparation process of the drug eluting stent is simple and is suitable for mass production.
Drawings
FIG. 1 is a schematic diagram of a drug eluting stent provided by the present invention;
wherein 1 is hydrogel grid, 2 is drug nano particles, and 3 is stent matrix.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
The sources of the components in the following examples are shown below:
degreasing and deoiling the bracket, and then placing the bracket into an ethanol acetone solution for ultrasonic cleaning and drying by cold air for later use.
Example 1
The embodiment provides a drug eluting stent, which is prepared by the following method:
(1) 2g of ammonium bifluoride, 3.5g of ammonium nitrate, 3g of triethanolamine, 50mL of n-pentane and 30mL of PBS are mixed and dissolved in a tetrafluoroethylene container, and 300W of ultrasonic waves are carried out for 30min to prepare corrosive liquid; immersing the bracket into corrosive liquid, locking the reaction kettle, placing the reaction kettle in an oven, keeping the temperature at 200 ℃ for 180 minutes, and taking out the reaction kettle; respectively carrying out ultrasonic cleaning by deionized water, ethanol and acetone;
(2) Preparing 10mg/mL rapamycin ethanol solution, fully soaking the stent at 20 ℃ for 50min, taking out and drying;
(3) 200g of mixed solution of 5% chitosan, 15% polyvinyl alcohol and 15% PVP is prepared, and the solvent is water; and (3) carrying out ultrasonic spraying (the spraying power is 10W, the frequency is 100kHz, the speed is 0.05 mL/min) on the surface of the stent, then carrying out ultraviolet curing for 30min at 380nm, and carrying out vacuum drying for 15min to obtain the drug eluting stent.
Example 2
The embodiment provides a drug eluting stent, which is prepared by the following method:
(1) 1mL of hydrogen fluoride (concentration is 40%), 3mL of nitric acid (concentration is 68%), 50mL of polyethylene glycol 400, 5g of AOT, 30mL of decane and 100mL of PBS are mixed and dissolved in a tetrafluoroethylene container, and 300W ultrasonic treatment is carried out for 30min to prepare corrosive liquid; immersing the bracket into corrosive liquid, locking the reaction kettle, placing the bracket in an oven, setting the temperature to 180 ℃, keeping the temperature for 60 minutes, and taking out the bracket; respectively carrying out ultrasonic cleaning by deionized water, ethanol and acetone;
(2) Preparing 10mg/mL rapamycin ethanol solution, fully soaking the stent at 10 ℃ for 30min, taking out and drying;
(3) Preparing 200g of mixed solution of 5% chitosan, 5% sodium alginate and 25% PVP, wherein the solvent is water; soaking the stent at 20 ℃ for 1min, lifting, placing the stent in an ultrafiltration centrifuge tube for spin coating at 550r/min, taking out, solidifying for 30min by using 350nm ultraviolet light, and finally drying in vacuum for 15min to obtain the drug eluting stent.
Example 3
The embodiment provides a drug eluting stent, which is prepared by the following method:
(1) 5g of ammonium bifluoride, 5.5g of potassium nitrate, 3.3g of polyethylene glycol 400, 20mL of diethyl ether, 10g of octadecane and 66mL of PBS are mixed and dissolved in a tetrafluoroethylene container, and 300W ultrasonic treatment is carried out for 30min to prepare corrosive liquid; immersing the bracket into corrosive liquid, locking the reaction kettle, placing the reaction kettle in an oven, setting the temperature to 150 ℃, keeping the temperature for 100min, and taking out; respectively carrying out ultrasonic cleaning by deionized water, ethanol and acetone;
(2) Preparing 15mg/mL rapamycin ethanol solution, fully soaking the stent at 10 ℃ for 60min, taking out and drying;
(3) 200g of mixed solution of 10% carbomer, 5% gelatin and 2% hyaluronic acid is prepared, and the solvent is water; soaking the bracket at 30 ℃ for 1min, lifting, placing the bracket in an ultrafiltration centrifuge tube for 300r/min for spin coating, taking out, solidifying for 30min by using 380nm ultraviolet light, and finally drying for 15min in vacuum to obtain the drug eluting bracket.
Example 4
This example provides a drug eluting stent that differs from example 1 only in that rapamycin is replaced with equal mass of everolimus, and the other steps are exactly the same as in example 1.
Example 5
This example provides a drug eluting stent differing from example 1 only in the substitution of rapamycin for equal mass daidzein, and the other steps are exactly the same as in example 1.
Example 6
This example provides a drug eluting stent that differs from example 1 only in that rapamycin is replaced with equal mass paclitaxel, and the other steps are identical to example 1.
Example 7
This example provides a drug eluting stent that differs from example 1 only in that ammonium bifluoride is replaced with equal mass of sodium fluoride, the other steps being exactly the same as example 1.
Example 8
This example provides a drug eluting stent differing from example 1 only in that ammonium nitrate is not added and the ammonium bifluoride content is increased to 5.5g, the other steps being exactly the same as in example 1.
Example 9
This example provides a drug eluting stent that differs from example 1 only in that no triethanolamine is added and the other steps are exactly the same as in example 1.
Example 10
The present example provides a drug eluting stent differing from example 1 only in that in step (1), the temperature was set at 100 ℃, and the stent was taken out after keeping the temperature for 400 minutes, and the other steps were exactly the same as in example 1.
Example 11
The present example provides a drug eluting stent differing from example 1 only in that in step (1), the temperature was set at 300 ℃, and after 50min of constant temperature, the stent was taken out, and the other steps were exactly the same as in example 1.
Example 12
This example provides a drug eluting stent differing from example 1 only in that in step (3), 200g of a mixed solution of 5% chitosan, 15% carbomer, and 15% methylcellulose was prepared, and the other steps were exactly the same as in example 1.
Example 13
This example provides a drug eluting stent differing from example 1 only in that in step (3), 200g of a mixed solution of 5% chitosan, 15% alginic acid, and 15% hyaluronic acid was prepared, and the other steps were exactly the same as in example 1.
Comparative example 1
The comparative example provides a non-hole-sealing drug eluting stent, which is prepared by the following method:
(1) 1mL of hydrogen fluoride (concentration is 40%), 3mL of nitric acid (concentration is 68%), 50mL of polyethylene glycol 400, 5g of AOT, 30mL of decane and 100mL of PBS are mixed and dissolved in a tetrafluoroethylene container, and 300W ultrasonic treatment is carried out for 30min to prepare corrosive liquid; immersing the bracket into corrosive liquid, locking the reaction kettle, placing the bracket in an oven, setting the temperature to 180 ℃, keeping the temperature for 60 minutes, and taking out the bracket; respectively carrying out ultrasonic cleaning by deionized water, ethanol and acetone;
(2) Preparing 10mg/mL rapamycin ethanol solution, fully soaking the stent at 15 ℃ for 35min, taking out and drying to obtain the non-hole-sealing drug eluting stent.
Comparative example 2
The comparative example provides a drug eluting stent prepared by the following method:
(1) 1mL of hydrogen fluoride (concentration is 40%), 3mL of nitric acid (concentration is 68%), 50mL of polyethylene glycol 400, 5g of AOT, 30mL of decane and 100mL of PBS are mixed and dissolved in a tetrafluoroethylene container, and 300W ultrasonic treatment is carried out for 30min to prepare corrosive liquid; immersing the bracket into corrosive liquid, locking the reaction kettle, placing the bracket in an oven, setting the temperature to 180 ℃, keeping the temperature for 60 minutes, and taking out the bracket; respectively carrying out ultrasonic cleaning by deionized water, ethanol and acetone;
(2) Preparing 10mg/mL rapamycin ethanol solution, fully soaking the stent at 5 ℃ for 20min, taking out and drying;
(3) 200g of mixed solution of 5% phosphatidylglycerol, 5% DSPE-PEG and 25% soybean lecithin is prepared, and the solvent is ethyl acetate; and (3) carrying out ultrasonic spraying (the spraying power is 15W, the frequency is 130kHz, the speed is 0.5 mL/min) on the surface of the stent, and carrying out vacuum drying for 30min to obtain the drug eluting stent.
Test example 1
Probability of restenosis test
Test sample: the drug eluting stents provided in examples 1-13, the drug eluting stents provided in comparative examples 1-2;
the testing method comprises the following steps: the experiment selects a healthy normal white pig with 35kg of test pig, performs pre-operation myoinfusion to induce anesthesia, performs suction anesthesia after successful anesthesia induction, and then performs tracheal intubation to establish a respiratory pathway and ear margin venipuncture to establish a vein pathway. After the animal is moved into an operating table, the region near femoral artery puncture parts at two sides is disinfected, femoral artery puncture is performed, a vascular sheath is inserted, and arterial access is established. The experimental animals are heparinized by intravenous injection of low molecular heparin and then are inserted into a contrast catheter for contrast, and different stents are implanted. Taking graft segment blood vessels after normal feeding of the animal after operation for 2 weeks, respectively extracting RNA, carrying out spot hybridization detection on transfection expression condition and carrying out pathological morphological analysis, and measuring the intimal hyperplasia degree;
the specific test results are shown in table 1 below:
TABLE 1
As shown in Table 2, the loss rate of the lumen of the stent matrix prepared by the invention is below 4%; the medicine is loaded in the micropores on the surface of the stent matrix, the micropores are sealed by the hydrogel, the medicine elution stent has no risk of coating falling off, and the occurrence probability of restenosis is reduced.
Test example 2
Burst test
Test sample: the drug eluting stent provided in example 13, the drug eluting stents provided in examples 7-13, the drug eluting stents provided in comparative examples 1-2;
the testing method comprises the following steps:
(1) Drug release from the drug eluting stent was studied in vitro with Phosphate Buffered Saline (PBS) at pH 6.4. The PBS solution was prepared by dissolving 1.79g of disodium hydrogen orthophosphate, 1.36g of potassium hydrogen orthophosphate, and 7.02g of sodium chloride in 1000mL of HPLC grade water. The solution is kept in an ultrasonic cleaner for 10min to dissolve;
(2) Arterial blood flow was simulated with peristaltic pump and silicone tubing, target vessel diameter 3mm, constant temperature 37 ℃ was set, and peristaltic pump speed was calibrated at 200mL/min flow. The stent is expanded to the inner wall of the silica gel tube, a peristaltic pump is started, and 10mL of eluent is respectively extracted at 1d, 15d and 30 d.
(3) Adding the extracted eluent into methanol to fix the volume to 50mL, and quantitatively detecting the content by liquid chromatography. Liquid chromatography measures drug content: the instrument is selected as follows: liquid chromatograph agilent 1260 index; chromatographic column: c18, 4.6x 500,5 μm; instrument operating parameters: detection wavelength: 278nm of rapamycin drug, column temperature: sample injection amount at 50 ℃): 10 μl, flow rate: 0.6mL/min.
The specific test results are shown in table 2 below:
TABLE 2
As shown in table 2, in the present invention, the drug is loaded in the micro-holes on the surface of the stent matrix, the micro-holes are sealed by hydrogel, the drug eluting stent has no risk of coating falling, the hydrogel is used for sealing the holes, the drug is prevented from being dissolved too fast to generate burst release, and 3-6% of the drug is released from the assembly of the coated stent at the end of day 1.
The applicant states that the invention is illustrated by the above examples as a drug eluting stent and a method of making and using it, but the invention is not limited to, i.e. it does not mean that the invention has to be carried out in dependence of, the above process steps. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of selected raw materials, addition of auxiliary components, selection of specific modes, etc. fall within the scope of the present invention and the scope of disclosure.
Claims (23)
1. A drug eluting stent, characterized in that the drug eluting stent comprises a stent matrix, a drug and a hydrogel; wherein, micro holes are arranged on the surface of the bracket matrix, and the medicine is loaded in the micro holes and sealed by hydrogel;
the micro holes are spherical, and the diameter of the micro holes is 0.2-1 mu m;
the hydrogel is a combination of chitosan, polyvinyl alcohol and polyvinylpyrrolidone with the mass ratio of (2-4) being 1 (2-4); or the mass ratio is 1 (0.5-2), namely (4-6) the combination of chitosan, sodium alginate and polyvinylpyrrolidone;
the number average molecular weight of the polyvinyl alcohol is 47000-98000;
the number average molecular weight of the polyvinylpyrrolidone is 8000-1300000.
2. The drug eluting stent of claim 1, wherein the surface micro-holes of the stent matrix have a distribution density of 4-8 ten thousand/mm 2 。
3. The drug eluting stent of claim 1, wherein the drug is selected from any one or a combination of at least two of rapamycin, everolimus, zotarolimus, paclitaxel, gingerol, losartan, daidzein, docetaxel, dexamethasone, methotrexate, dextran, mitomycin, heparin sodium, doxorubicin hydrochloride, hirudin, argatroban, dipyridamole, prostacyclin, nitroglycerin, nitroprusside, suramin, endostatin, serotonin blockers, steroids, or oligopeptides.
4. The drug eluting stent of claim 1, wherein the drug loading density of the drug eluting stent is 1-5 μg/mm 2 。
5. A method of preparing a drug eluting stent as defined in any of claims 1 to 4, comprising the steps of:
(1) Carrying out chemical corrosion treatment on the surface of the bracket matrix, and forming micro holes on the surface of the bracket matrix;
(2) Immersing the stent matrix treated in the step (1) in a drug solution to load the drug into the micropores;
(3) And (3) sealing the stent matrix treated in the step (2) by using hydrogel to obtain the drug eluting stent.
6. The method of preparing a drug eluting stent of claim 5, wherein in step (1), the step of chemically etching is: placing the bracket matrix and the corrosive liquid into a reaction kettle, and reacting under the conditions of high temperature and high pressure.
7. The method of preparing a drug eluting stent of claim 6, wherein the etching solution includes an etchant, a surfactant, and a solvent.
8. The method for preparing a drug eluting stent of claim 7, wherein the corrosive liquid is composed of the following components, based on 100% of the total mass of the corrosive liquid: 0.5-10% of corrosive agent, 0.1-5% of surfactant and the balance of solvent.
9. The method of preparing a drug eluting stent of claim 7, wherein the etchant is selected from any one or a combination of at least two of hydrofluoric acid, ammonium fluoride, ammonium bifluoride, nitric acid, sodium nitrate, ammonium nitrate, potassium nitrate, or ammonium bifluoride.
10. The method for preparing a drug eluting stent of claim 7, wherein the surfactant is selected from any one or a combination of at least two of diisooctyl succinate, sodium dodecyl benzene sulfonate, cetyltrimethylammonium bromide, or triethanolamine.
11. The method of preparing a drug eluting stent of claim 7, wherein the solvent is selected from any one or a combination of at least two of PBS solvent, TES buffer, acetone, diethyl ether, isopropanol, n-pentane, cyclopentane, decane, octadecane, or polyethylene glycol.
12. The method for preparing a drug eluting stent of claim 6, wherein the reaction temperature is 110-250 ℃ and the reaction time is 60-120 min.
13. The method of preparing a drug eluting stent of claim 5, wherein in step (2), the solvent of the drug solution is selected from any one or a combination of at least two of methanol, ethanol, or methylene chloride.
14. The method of claim 5, wherein in step (2), the concentration of the drug solution is 10-50 mg/mL.
15. The method of preparing a drug eluting stent of claim 5, wherein in step (2), the temperature of the impregnation is 0-20 ℃ and the time of the impregnation is 30-120 min.
16. The method for preparing a drug eluting stent of claim 5, wherein in step (3), the step of sealing the hole is: ultrasonically spraying the mixed solution of the hydrogel to the surface of a stent matrix, and then solidifying and drying to finish hole sealing to obtain the drug eluting stent;
or, the hole sealing step is as follows: soaking a stent matrix in a mixed solution of hydrogel, lifting, centrifuging, solidifying and drying to finish hole sealing, and obtaining the drug eluting stent.
17. The method of claim 16, wherein in step (3), the solvent of the mixed solution of hydrogels is water.
18. The method of claim 16, wherein in step (3), the solid content of the mixed solution of hydrogels is 10-50-wt%.
19. The method of claim 16, wherein in step (3), the ultrasonic spraying is performed at a power of 3-15W, a frequency of 50-150kHz, and a rate of 0.01-2 mL/min.
20. The method of preparing a drug eluting stent of claim 16, wherein in step (3), the temperature of the impregnation is 20-40 ℃ and the time of the impregnation is 0.5-10 min.
21. The method of claim 16, wherein in step (3), the rotational speed of the centrifugation is 100-1000 r/min.
22. The method of claim 16, wherein in step (3), the curing is ultraviolet curing, the wavelength of ultraviolet curing is 300-380nm, and the time of ultraviolet curing is 20-40 min.
23. Use of a drug eluting stent as defined in any of the claims 1 to 4 for the preparation of a product for the treatment of atherosclerosis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211011374.4A CN115317675B (en) | 2022-08-23 | 2022-08-23 | Drug eluting stent and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211011374.4A CN115317675B (en) | 2022-08-23 | 2022-08-23 | Drug eluting stent and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115317675A CN115317675A (en) | 2022-11-11 |
CN115317675B true CN115317675B (en) | 2024-02-27 |
Family
ID=83926135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211011374.4A Active CN115317675B (en) | 2022-08-23 | 2022-08-23 | Drug eluting stent and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115317675B (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1919353A (en) * | 2006-08-14 | 2007-02-28 | 董何彦 | Preparation method of metal support surface micro blind hole drug-loaded layer |
CN101361686A (en) * | 2008-10-13 | 2009-02-11 | 王显 | Blood vessel drug eluting stent |
CN101869723A (en) * | 2009-04-27 | 2010-10-27 | 赵菁 | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method |
CN102309368A (en) * | 2010-07-09 | 2012-01-11 | 微创医疗器械(上海)有限公司 | Body lumen drug-carrying bracket and preparation method thereof |
CN104888282A (en) * | 2015-05-05 | 2015-09-09 | 乐普(北京)医疗器械股份有限公司 | Degradable zinc-based micropore drug-loaded support and preparation method thereof |
CN105797207A (en) * | 2016-04-01 | 2016-07-27 | 北京联合大学 | Drug release carrier on metal substrate and preparation method thereof |
CN105944155A (en) * | 2016-03-24 | 2016-09-21 | 乐普(北京)医疗器械股份有限公司 | Drug eluting stent and manufacturing method and application thereof |
CN110665072A (en) * | 2019-11-23 | 2020-01-10 | 吉林省蔚来生物科技有限公司 | Targeted drug release interventional medical instrument and preparation method thereof |
CN111529150A (en) * | 2020-04-28 | 2020-08-14 | 东南大学苏州医疗器械研究院 | Sinus duct stent and preparation method thereof |
CN113476315A (en) * | 2021-07-02 | 2021-10-08 | 何平蓉 | Long-acting moisturizing slow-release microsphere applied to sun screen and preparation method thereof |
-
2022
- 2022-08-23 CN CN202211011374.4A patent/CN115317675B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1919353A (en) * | 2006-08-14 | 2007-02-28 | 董何彦 | Preparation method of metal support surface micro blind hole drug-loaded layer |
CN101361686A (en) * | 2008-10-13 | 2009-02-11 | 王显 | Blood vessel drug eluting stent |
CN101869723A (en) * | 2009-04-27 | 2010-10-27 | 赵菁 | Composite medicament stent for inhibiting cardiovascular restenosis and preparation method |
CN102309368A (en) * | 2010-07-09 | 2012-01-11 | 微创医疗器械(上海)有限公司 | Body lumen drug-carrying bracket and preparation method thereof |
CN104888282A (en) * | 2015-05-05 | 2015-09-09 | 乐普(北京)医疗器械股份有限公司 | Degradable zinc-based micropore drug-loaded support and preparation method thereof |
CN105944155A (en) * | 2016-03-24 | 2016-09-21 | 乐普(北京)医疗器械股份有限公司 | Drug eluting stent and manufacturing method and application thereof |
CN105797207A (en) * | 2016-04-01 | 2016-07-27 | 北京联合大学 | Drug release carrier on metal substrate and preparation method thereof |
CN110665072A (en) * | 2019-11-23 | 2020-01-10 | 吉林省蔚来生物科技有限公司 | Targeted drug release interventional medical instrument and preparation method thereof |
CN111529150A (en) * | 2020-04-28 | 2020-08-14 | 东南大学苏州医疗器械研究院 | Sinus duct stent and preparation method thereof |
CN113476315A (en) * | 2021-07-02 | 2021-10-08 | 何平蓉 | Long-acting moisturizing slow-release microsphere applied to sun screen and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN115317675A (en) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3803857B2 (en) | Polymer coating for controlled delivery of active agents | |
EP3193954B1 (en) | Medical balloon coated with therapeutic agent, carboxylic acid, and salt thereof | |
CN101678154A (en) | Degradation associated drug delivery for drug eluting stent and medical device coatings | |
EP2872192B1 (en) | Catheter with drug coating | |
JP2005530561A (en) | Silicone mixtures and composites for drug delivery | |
CN113648114B (en) | Coated stent and preparation method thereof | |
CN112402702A (en) | Drug coating composition and drug coating balloon | |
CN115317675B (en) | Drug eluting stent and preparation method and application thereof | |
IL175287A (en) | Method for preparing drug eluting medical devices and devices obtained therefrom | |
JP5217026B2 (en) | Stent and manufacturing method thereof | |
RU2325193C2 (en) | Vascular stent | |
CN115192780A (en) | Rapamycin drug balloon and preparation method and application thereof | |
CN111214748A (en) | Drug eluting balloon and balloon catheter | |
CN107496998B (en) | Peripheral drug eluting stent and preparation and application thereof | |
CN111588914A (en) | Medicine coating for interventional or implanted medical apparatus and preparation method thereof | |
US20240082458A1 (en) | Tubular material, preparation method therefor and use thereof | |
CN100336566C (en) | Method for coating medicine coating stent and special device thereof | |
DK2854887T3 (en) | Coating of balloon catheters | |
US7892595B2 (en) | Implantable device coating system and method | |
CN111714260B (en) | Bracket and application thereof | |
Song et al. | Ultrasound controlled paclitaxel releasing system—A novel method for improving the availability of coronary artery drug coated balloon | |
KR102522542B1 (en) | Drug-eluting stent | |
CN100413540C (en) | Gene carrying rack and its producing method and use | |
JP7275269B2 (en) | Medical tube body and its preparation method | |
CN204909753U (en) | Assist and to absorb spraying lining structure that support carries out medicine spraying |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |